What is the primary objective of FDA 21 CFR Part 11?

The primary objective of FDA 21 CFR Part 11 is to establish criteria under which the Agency considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records and handwritten signatures executed on paper. This equivalency standard, stated in §11.1(a), ensures authenticity, integrity, confidentiality (when appropriate), and non-repudiation through controls like validation (§11.10(a)), secure audit trails (§11.10(e)), access limitations (§11.10(d)), and electronic signature requirements (§§11.50–11.300).

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

FDA 21 CFR Part 11 applies to organizations using electronic records created, modified, maintained, archived, retrieved, or transmitted under FDA predicate rules, or submitting accepted electronic records to the Agency. Per §11.1(b), scope includes predicate-rule-required records relied upon in lieu of paper, even if paper exists, and legally binding electronic signatures. Exclusions cover certain food records (§11.1(f)–(p)) and paper transmitted electronically.

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal controls, validation (§11.10(a)), SOPs, training (§11.10(i)), and inspection readiness (§11.1(e)), with systems and documentation available for FDA review. FDA’s 2003 guidance emphasizes risk-based approaches without mandating external validation.

How often should an assessment for FDA 21 CFR Part 11 be performed?

FDA 21 CFR Part 11 does not prescribe a fixed frequency for assessments; organizations must perform periodic reviews via change control, risk assessments, and operational checks to maintain compliance. FDA’s 2003 guidance supports risk-based validation and ongoing fitness-for-use evaluations, integrated with quality systems for system changes, periodic audits, and predicate rule requirements.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 can result in FDA enforcement actions including Form 483 observations, warning letters, product holds, import alerts, fines up to $10,000 per violation, and injunctions. Violations often trigger predicate rule enforcement (e.g., CGMP failures), as clarified in 2003 guidance, with risks to data integrity leading to recalls or submission rejections.

An FDA 21 CFR Part 11 be mapped to other international frameworks?

Yes, FDA 21 CFR Part 11 control objectives such as audit trails, access controls, and electronic signatures can be mapped to frameworks like EU Annex 11. However, Part 11’s narrow scope and 2003 enforcement discretion differ; mapping requires risk-based analysis of closed/open systems (§§11.10, 11.30) and predicate alignment.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step to implement FDA 21 CFR Part 11 is to establish a formal applicability framework mapping predicate rules to electronic records and determining business reliance. Per 2003 guidance, document in SOPs whether records are Part 11 scope (relied upon electronically vs. paper), classify systems as closed/open (§11.3), and prioritize high-risk controls.

What is the primary objective of ISO 27701?

ISO 27701 establishes requirements for a Privacy Information Management System (PIMS) to manage privacy risks in processing personally identifiable information (PII). It extends management system clauses (4–10) for context, leadership, planning, support, operation, evaluation, and improvement, adding Annex A controls for PII controllers (e.g., lawful basis, data subject rights) and Annex B for processors (e.g., processing agreements, subprocessor management). The PDCA cycle ensures continual improvement and auditable evidence like Records of Processing Activities (RoPA) and Statements of Applicability (SoA).

Who is legally or professionally required to comply with ISO 27701?

ISO 27701 applies to any organization acting as a PII controller, processor, or both, regardless of size or sector. Controllers determine processing purposes and must implement transparency, consent, and rights fulfillment controls; processors follow controller instructions with confidentiality and assistance obligations. It targets PII-heavy entities in finance, healthcare, SaaS, and supply chains, enabling demonstrable accountability under privacy laws without being legally mandatory itself.

Does ISO 27701 require an external audit or third-party certification?

ISO 27701 certification involves external audits by accredited third-party bodies, typically in a two-stage process. Stage 1 reviews documentation (e.g., scope, SoA, RoPA); Stage 2 verifies implementation via interviews and evidence sampling. The 2026 edition functions as an extension to ISO 27001 certification, valid for three years with annual surveillance audits and recertification at year three.

How often should an assessment for ISO 27701 be performed?

ISO 27701 requires ongoing internal audits, management reviews, and continual improvement via the PDCA cycle. Certification maintenance demands annual surveillance audits post-initial three-year certification, plus periodic internal audits, risk reassessments, and management reviews to evaluate PIMS effectiveness, incidents, and nonconformities.

What are the consequences of non-compliance with ISO 27701?

Non-compliance with ISO 27701 risks certification denial, suspension, or withdrawal, plus indirect regulatory fines from unproven privacy accountability. Lacking PIMS evidence exposes organizations to privacy law penalties (e.g., GDPR fines up to 4% global turnover), reputational damage, lost contracts, and supply-chain exclusion, as it fails to demonstrate operational controls for PII risks.

An ISO 27701 be mapped to other international frameworks?

Yes, ISO 27701 includes annex mappings to frameworks like GDPR (Annex D), ISO/IEC 29100 (Annex C), and ISO/IEC 27018/29151 (Annex E). Annex F details relationships with ISO 27001/27002, enabling integrated risk processes, shared SoAs, and unified audits for PIMS within existing security governance.

What is the first step to begin implementing ISO 27701?

The first step is defining PIMS context and scope per Clause 4, identifying PII processing activities and controller/processor roles. Conduct a gap analysis against Clauses 4–10 and Annexes A/B, inventory PII flows, and produce initial documentation including RoPA and draft SoA to prioritize privacy risks and controls.

Standards Comparison

FDA 21 CFR Part 11 vs ISO 27701

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation for electronic records and signatures equivalency

ISO 27701

Voluntary

2019

International standard for privacy information management systems

Quick Verdict

FDA 21 CFR Part 11 mandates electronic record trustworthiness for US life sciences, ensuring data integrity via validation and audit trails. ISO 27701 provides voluntary PIMS certification for global PII privacy governance. Pharma firms adopt Part 11 for FDA compliance; others seek 27701 for privacy assurance.

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11 Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

Medium

Implementation Time

18-24 months

Key Features

Establishes equivalency for electronic records to paper
Mandates secure time-stamped audit trails
Requires closed/open system controls distinction
Enforces unique linked electronic signatures
Supports risk-based validation enforcement discretion

Privacy Management

ISO 27701

ISO/IEC 27701:2026 Privacy Information Management System

Cost

€€€

Complexity

High

Implementation Time

6-12 months

Key Features

Establishes Privacy Information Management System (PIMS)
Role-specific controls for PII controllers and processors
Integrates with ISO/IEC 27001 ISMS structure
Provides GDPR and regulatory mappings in annexes
Functions as an extension to ISO/IEC 27001 certification

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule records, employing a risk-based approach with narrow scope interpretation per 2003 FDA guidance.

Key Components

Subparts A-C: scope, electronic records controls (§11.10 closed systems, §11.30 open systems), signatures (§11.50-11.300).
Core controls: validation, audit trails, access limits, operational/authority/device checks, training, accountability policies.
Principles: authenticity, integrity, non-repudiation; enforcement discretion on some elements but predicate rules enforced.
No certification; compliance via inspection readiness.

Why Organizations Use It

Mandatory for electronic reliance in pharma, devices, biologics to avoid enforcement.
Mitigates data integrity risks, enables digital transformation.
Builds trust, accelerates inspections, improves quality via traceability.

Implementation Overview

Risk-based CSV lifecycle: scope records, GAMP categorization, IQ/OQ/PQ validation, SOPs/training, supplier governance. Applies to life sciences; phased 18-24 months typical, ongoing via change control.

ISO 27701 Details

What It Is

ISO/IEC 27701:2026 is the international standard for establishing, implementing, maintaining, and improving a Privacy Information Management System (PIMS). It provides requirements and guidance for PII controllers and processors, using a risk-based PDCA approach tightly integrated with ISO/IEC 27001.

Key Components

Clauses 4–10: context, leadership, planning, support, operation, evaluation, improvement
**Annex AController controls (lawful basis, DSARs, retention)
**Annex BProcessor controls (contracts, sub-processors, assistance)
Mappings: GDPR (Annex D), ISO 29100, 27018
Certification: SoA, 3-year cycle with audits

Why Organizations Use It

Demonstrates accountability for GDPR/CCPA compliance
Manages privacy risks and harms to individuals
Enhances trust, procurement, supply-chain differentiation
Reduces fines, incidents via evidence generation

Implementation Overview

Phased: gap analysis, risk treatment, controls, audits
All sizes/industries processing PII; global applicability
6–12 months with ISMS; integrated audits possible

Key Differences

Aspect	FDA 21 CFR Part 11	ISO 27701
Scope	Electronic records/signatures trustworthiness in FDA-regulated activities	Privacy Information Management System for PII processing
Industry	Life sciences, pharma, medical devices (US-focused)	All sectors handling PII globally
Nature	Mandatory US FDA regulation with enforcement discretion	Voluntary international certification standard
Testing	Risk-based system validation, audit trails, FDA inspections	Internal audits, management reviews, third-party certification
Penalties	Warning letters, product holds, enforcement actions	Loss of certification, no direct legal penalties

Scope

FDA 21 CFR Part 11

Electronic records/signatures trustworthiness in FDA-regulated activities

ISO 27701

Privacy Information Management System for PII processing

Industry

FDA 21 CFR Part 11

Life sciences, pharma, medical devices (US-focused)

ISO 27701

All sectors handling PII globally

Nature

FDA 21 CFR Part 11

Mandatory US FDA regulation with enforcement discretion

ISO 27701

Voluntary international certification standard

Testing

FDA 21 CFR Part 11

Risk-based system validation, audit trails, FDA inspections

ISO 27701

Internal audits, management reviews, third-party certification

Penalties

FDA 21 CFR Part 11

Warning letters, product holds, enforcement actions

ISO 27701

Loss of certification, no direct legal penalties

Frequently Asked Questions

Common questions about FDA 21 CFR Part 11 and ISO 27701

FDA 21 CFR Part 11 FAQ

ISO 27701 FAQ

You Might also be Interested in These Articles...

From Reactive Gatekeeper to Proactive Strategist: How Compliance Software Reshapes the Compliance Professional's Day

Discover how compliance software automates monitoring, delivers real-time insights, and transforms compliance pros from reactive gatekeepers to proactive strate

The Tool Landscape for Reaching and Maintaining ISO 27001 Compliance

Discover top ISO 27001 compliance tools, their pros/cons, implementation steps, costs, and benefits. Streamline your path to certification and ongoing complianc

The CIS Controls v8.1 Evidence Pack: What Auditors Ask For (and How to Produce Proof Fast)

Fail CIS Controls v8.1 audits due to missing evidence? Get the blueprint: exact artifacts auditors want, repository structure, and automation from security tool

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how FDA 21 CFR Part 11 and ISO 27701 compare against other standards

Other FDA 21 CFR Part 11 Comparisons

Other ISO 27701 Comparisons

Quick Verdict

What It Is

Key Components

Subparts A-C: scope, electronic records controls (§11.10 closed systems, §11.30 open systems), signatures (§11.50-11.300).

Core controls: validation, audit trails, access limits, operational/authority/device checks, training, accountability policies.

Principles: authenticity, integrity, non-repudiation; enforcement discretion on some elements but predicate rules enforced.

No certification; compliance via inspection readiness.

What It Is

Key Components

Clauses 4–10: context, leadership, planning, support, operation, evaluation, improvement

**Annex AController controls (lawful basis, DSARs, retention)

**Annex BProcessor controls (contracts, sub-processors, assistance)

Mappings: GDPR (Annex D), ISO 29100, 27018

Certification: SoA, 3-year cycle with audits

Aspect

FDA 21 CFR Part 11

ISO 27701

Scope

Electronic records/signatures trustworthiness in FDA-regulated activities

Privacy Information Management System for PII processing

Industry

Life sciences, pharma, medical devices (US-focused)

All sectors handling PII globally

Nature

Mandatory US FDA regulation with enforcement discretion

Voluntary international certification standard

Testing

Risk-based system validation, audit trails, FDA inspections

Internal audits, management reviews, third-party certification

Penalties

Warning letters, product holds, enforcement actions

Loss of certification, no direct legal penalties